Asthma / tyrosine

Single nucleotide polymorphisms in protein-tyrosine phosphatase receptor-type delta for the diagnosis of susceptibility to asthma

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú

Logáil Isteach / Cláraigh

FEDERALLY SPONSORED RESEARCH STATEMENT Not applicable. REFERENCE TO A SEQUENCE LISTING A "Sequence Listing" with sequences labeled SEQ ID NO: 1-75 is attached hereto. A compact disc containing a Computer Readable Form (CRF) labeled "SEQUENCE LISTING.txt" is incorporated by reference. The copy in CRF

Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú

Logáil Isteach / Cláraigh

FIELD OF THE INVENTION This invention relates to compounds which are inhibitors of protein tyrosine kinases, such as the Janus kinases, and to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases comprising administering to a

Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú

Logáil Isteach / Cláraigh

FIELD OF THE INVENTION This invention relates to compounds which are inhibitors of protein tyrosine kinases, such as the Janus kinases, and to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases comprising administering to a

Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú

Logáil Isteach / Cláraigh

The present invention relates to a series of substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to bioisosteres of quinoline and quinazoline derivatives which exhibit protein

Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases)

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú

Logáil Isteach / Cláraigh

FIELD OF THE INVENTION The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of

Treatment of severe persistant asthma with masitinib

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú

Logáil Isteach / Cláraigh

The present invention relates to the treatment of severe persistent asthma, and in particular severe persistent corticosteroid-dependent or corticosteroid-resistant asthma, comprising administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically

Tyrosine amide derivatives as Rho-kinase inhibitors

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú

Logáil Isteach / Cláraigh

CROSS REFERENCES TO RELATED APPLICATIONS This application claims priority to European Patent Application No. 17153785.5 filed on Jan. 30, 2017, which is incorporated herein by reference in its entirety. BACKGROUND OF THE INVENTION Field of the Invention The present invention relates to compounds

RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú

Logáil Isteach / Cláraigh

FIELD OF THE INVENTION The present invention relates to the field of interfering RNA compositions for silencing spleen tyrosine kinase (Syk) and for treatment of a Syk-related inflammatory condition. Such conditions include allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma,

RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú

Logáil Isteach / Cláraigh

FIELD OF THE INVENTION The present invention relates to the field of interfering RNA compositions for silencing spleen tyrosine kinase (Syk) and for treatment of a Syk-related inflammatory condition. Such conditions include allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma,

RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú

Logáil Isteach / Cláraigh

FIELD OF THE INVENTION The present invention relates to the field of interfering RNA compositions for silencing spleen tyrosine kinase (Syk) and for treatment of a Syk-related inflammatory condition. Such conditions include allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma,

Modulators of protein tyrosine phosphatases (PTPases)

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú

Logáil Isteach / Cláraigh

FIELD OF THE INVENTION The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of

Modulators of protein tyrosine phosphatases (PTPASES)

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú

Logáil Isteach / Cláraigh

FIELD OF THE INVENTION The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of

Modulators of protein tyrosine phosphatases (PTPases)

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú

Logáil Isteach / Cláraigh

FIELD OF THE INVENTION The present invention relates to novel compounds, to methods for their preparation, to compositions comprising the compounds, to the use of these compounds as medicaments and their use in therapy, where such compounds of Formula 1 are pharmacologically useful inhibitors of

Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú

Logáil Isteach / Cláraigh

FIELD OF THE INVENTION This invention relates to compounds which are inhibitors of protein tyrosine kinases, such as the Janus kinases, and to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases comprising administering to a

Mice with targeted tyrosine kinase, lyn, disruption

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú

Logáil Isteach / Cláraigh

This invention relates to model systems for autoimmune disease. In particular, the invention relates to animals, preferably mice, with a specifically-targeted disruption of a gene encoding a protein tyrosine kinase enzyme of the src family. Mice according to the invention show a variety of

asthma/tyrosine

Single nucleotide polymorphisms in protein-tyrosine phosphatase receptor-type delta for the diagnosis of susceptibility to asthma

Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof

Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof

Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases)

Treatment of severe persistant asthma with masitinib

Tyrosine amide derivatives as Rho-kinase inhibitors

RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

Modulators of protein tyrosine phosphatases (PTPases)

Modulators of protein tyrosine phosphatases (PTPASES)

Modulators of protein tyrosine phosphatases (PTPases)

Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors

Mice with targeted tyrosine kinase, lyn, disruption

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht